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Introduction: A stepwise approach to the functional assessment of
lung resection candidates is widely accepted, and this approach
incorporates the measurement of exercise peak VO2 when spirome-
try and radionuclear studies suggest medical inoperability. A new
functional operability (FO) algorithm incorporates peak exercise
VO2 earlier in the preoperative assessment to determine which
patients require preoperative radionuclear studies. This algorithm
has not been studied in a multicenter study.
Methods: The CALGB (Cancer and Leukemia Group B) performed
a prospective multi-institutional study to investigate the use of
primary exercise VO2 measurement for the prediction of surgical
risk. Patients with known or suspected resectable non-small cell lung
cancer (NSCLC) were eligible. Exercise testing including measure-
ment of peak oxygen uptake (VO2), spirometry, and single breath
diffusion capacity (DLCO) was performed on each patient. Nuclear
perfusion scans were obtained on selected high-risk patients. After
surgery, morbidity and mortality data were collected and correlated
with preoperative data. Mortality and morbidity were retrospectively
compared by algorithm-based risk groups.
Results: Three hundred forty-six patients with suspected lung can-
cer from nine institutions underwent thoracotomy with or without
resection; 57 study patients did not undergo thoracotomy. Patients
who underwent surgery had a median survival time of 30.9 months,
whereas patients who did not undergo surgery had a median survival
time of 15.6 months. Among the 346 patients who underwent
thoracotomy, 15 patients died postoperatively (4%), and 138 pa-
tients (39%) exhibited at least one cardiorespiratory complication
postoperatively. We found that patients who had a peak exercise
VO2 of 65% of predicted (or a peak VO2/kg 16 ml/min/kg)
were more likely to suffer complications (p  0.0001) and were
also more likely to have a poor outcome (respiratory failure or
death) if the peak VO2 was 15 ml/min/kg (p  0.0356). We also
found a subset of 58 patients who did not meet FO algorithm
criteria for operability, but who still tolerated lung resection with
a 2% mortality rate.
Conclusions: Our data provide multicenter validation for the use of
exercise VO2 for preoperative assessment of lung cancer patients,
and we encourage an aggressive approach when evaluating these
patients for surgery.
Key Words: Algorithm, Single breath diffusion capacity, Exercise,
Forced expiratory volume in 1 second (FEV1), Lung cancer, Lung
resection, Preoperative, Risk, Spirometry, VO2.
(J Thorac Oncol. 2007;2: 619–625)
Lung cancer is the leading cause of cancer-related death inNorth America, and 213,380 new cases of lung cancer are
anticipated in 2007.1 Only 15% of these patients will survive
for 5 years, and survival is closely linked with lung resection.
Because 90% of lung cancers occur in current or former
smokers, and chronic obstructive pulmonary disease itself is
an independent risk factor for lung cancer,2 most of these
patients face surgery with the risk of significant comorbidi-
ties. Lung resection is still considered a high-risk surgical
procedure,3 and the risks entail unacceptable outcomes in-
cluding both postoperative mortality and prolonged mechan-
ical ventilation in certain patients.
Although preoperative measurement of oxygen uptake
(VO2) during exercise has been examined extensively in lung
resection candidates,4–17 no single parameter has been estab-
lished as the best predictor of perioperative risk in lung
cancer patients. Instead, exercise testing with measurement of
VO2 has been recommended as a part of a stepwise preoper-
ative evaluation for patients who face lung resection,18 with
the recognition that operative risk is believed to be prohibi-
tive in patients with a peak VO2 10 ml/min/kg or 40% of
predicted.
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When to perform exercise VO2 measurement in the
workup of potential lung resection patients is less clear.
Guidelines published by the American College of Chest
Physicians (ACCP)18 and the British Thoracic Society19 rec-
ommend exercise testing only in individuals who fail spirom-
etry, diffusion capacity, and nuclear differential perfusion
scan based measurements. In these algorithms, exercise VO2
measurement is a test of last resort. An alternate stepwise
algorithm has been proposed15 and prospectively evaluated in
137 consecutive patients in a single-institution trial.11 This
functional operability (FO) algorithm uses exercise VO2 in all
patients who exhibit either a forced expiratory volume in 1
second (FEV1) or single breath diffusion capacity (DLCO) of
less than 80% of predicted.20 The Cancer and Leukemia
Group B (CALGB) protocol 9238 was a prospective cooper-
ative group trial conducted to assess whether patients with an
exercise peak VO2 15 (or 60% of predicted) would tolerate
lung resection, regardless of FEV1. We also used the multi-
institutional data from CALGB 9238 to retrospectively vali-
date the FO algorithm.
METHODS
Subjects and Design
CALGB 9238 was designed to collect preoperative
pulmonary function and exercise data, with particular atten-
tion to high-risk patients who traditionally might be denied
surgery because of baseline pulmonary function. The preop-
erative FEV1 of 900 ml (or 33% of predicted) had been the
previous historical standard for medical inoperability in
CALGB surgical trials, so patients with lung cancer who did
not meet this CALGB standard were categorized as high risk
before surgery, and their surgical mortality was monitored
during the trial, with the intent of trial closure if excess
mortality was observed.
Patients with potentially resectable lung cancer were
eligible for enrollment. Additional eligibility requirements
included adequate laboratory values (hemoglobin, PaO2, he-
matocrit, potassium), an electrocardiogram that was not sug-
gestive of serious cardiac problems, and no serious medical
illness limiting survival to less than 2 years. After registra-
tion, patients underwent pulmonary function testing and ex-
ercise testing as described below. Previous CALGB thoracic
surgical studies have used an FEV1 900 ml or 33% of
predicted as the minimal entry criteria, so patients were
categorized into one of three patient populations based on
these pulmonary function standards: high-risk population,
including patients with predictive postoperative FEV1 900
ml (or 33% of predicted) and maximal VO2 of 15 ml/kg;
low-risk population, including patients with an initial FEV1
70% who were assumed to have a predicted postoperative
FEV1 900 ml and were not required to undergo a perfusion
lung scan, and patients with predicted postoperative FEV1
900 ml or 33%, and the very high risk population of patients
with either a submaximal exercise test or both predictive
postoperative FEV1 900 ml and maximal VO2 15 ml/kg.
All high-risk patients and low-risk patients were to undergo
thoracotomy; the treatment of remaining patients was at the
physician’s discretion. The physician discretion group was
not an intermediate risk group; rather, they were patients who
were deemed not to be surgical candidates by the CALGB
algorithm. Nonetheless, a substantial number of these patients
were allowed to go ahead with surgery based on their sur-
geon’s assessment that such treatment offered them the best
chance of long-term survival of their cancer.
Preoperative Pulmonary Function
Measurements
Arterial blood gases were performed on room air.
Spirometry provided measurement of the forced vital capac-
ity (FVC) and the FEV1. The single breath diffusion capacity
(DLCO) was corrected for serum hemoglobin, and lung
volumes (by helium dilution or nitrogen washout technique)
were obtained for determination of the total lung capacity
(TLC). Tests were performed based on accepted standards,
and individual laboratories set predicted values based on local
standards.
Preoperative Pulmonary Exercise Testing
Subjects underwent a symptom-limited incremental
ramp workload study on a cycle ergometer, the workload rate
determined by individual investigators. All institutions used
MedGraphics metabolic carts retrofitted with standardized
exercise software (MedGraphics, St. Paul, MN). A breath-by-
breath analysis system was used to validate the exercise equip-
ment at each institution. Exercise and rest measurements in-
cluded oxygen consumption, carbon dioxide production (VCO2),
and ventilation (VE). Peak oxygen consumption (VO2) was
defined as the highest achieved during exercise. This value was
normalized for patient mass and also expressed as a percent of
predicted based on the equations of Wasserman and Whipp.21
Split- Function Studies
Technetium-99 macroaggregate perfusion scans (split-
function studies) were used to quantitate the contribution of
postresectional lung parenchyma to lung function, when
available at individual centers. The predicted postoperative
(ppo) value for FEV1 and DLCO was calculated based on the
formula proposed by Olsen et al.22
Measurement of Mortality and Postoperative
Morbidity
The measured outcomes included cardiorespiratory
complications and surgical morality (including hospital
deaths within 30 days or never released from hospital).
Cardiorespiratory complications were defined as deep venous
thrombosis, pulmonary embolus, dysrhythmia, or myocardial
infarction or respiratory complications (atelectasis, pneumo-
nia, acute postoperative increase in PCO2, requirement for
supplemental oxygen at discharge, need for postoperative
ventilation, reintubation, or tracheotomy). Surgical mortality
was defined as all deaths occurring during the hospitalization
in which the operation was performed, regardless of the
number of days after surgery, and all deaths occurring after
hospitalization but within 30 days of the procedure unless the
cause of death was clearly unrelated to the operation. Sur-
vival time was defined as the time between study entry and
death. Complications were also classified as poor outcome
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(death, or respiratory failure defined as postoperative me-
chanical ventilation 24 hours) denoting unacceptable out-
comes and complicated course (cardiorespiratory complica-
tions, as listed in Table 5).
Statistical Methods
Three patient populations were to be studied as part of
this study: low-risk patients, high-risk patients, and very
high-risk patients who would be offered surgery at the phy-
sician’s discretion. The accrual goal was 400 patients, includ-
ing 90 high-risk patients, a patient population that had been
traditionally excluded from lung resection. The high-risk
patient population was studied to determine whether such
patients could undergo lung resection without experiencing
significant morbidity and complication. A three-stage design
with a type I and II error of 0.049 and 0.197, respectively,
was used to differentiate between a 10% and 20% postoper-
ative mortality rates. Exact 95% binomial confidence inter-
vals were calculated for postoperative mortality rate, as well
as other dichotomized outcome variables. The product limit
estimator developed by Kaplan and Meier was used to graph-
ically describe the survival experience of various subgroups
of patients that participated in CALGB 9238.
RESULTS
CALGB 9238 was activated on August 15, 1993 and
closed to patient accrual on July 15, 1998. During this period,
422 patients were registered to the study of whom 403
patients have data that are adequate to determine outcome and
baseline characteristics. The characteristics of these 403 pa-
tients are summarized in Table 1.
The outcomes of the pulmonary function tests and the
nuclear perfusion scan were used to assign patients to risk
groups as shown in Figure 1. Patients with FEV1 70% or
FEV1-ppo 33% and FEV1-ppo 900 ml were assigned to
thoracotomy in the low-risk group (254 patients). The 63
patients that did not fall into the low-risk group but reached
an exercise peak VO2 15 ml/kg were assigned to thoracot-
omy in the high-risk group. This resulted in 317 patients
being assigned to thoracotomy, 86 patients being assigned to
the very high-risk group with the decision for thoracotomy
deferred to physician discretion despite adverse PFT and
exercise results. Table 2 summarizes the extent of resection
for each patient group.
Of the 403 patients, 346 had a thoracotomy with or
without resection. The remaining 57 patients did not undergo
thoracotomy. Among the 346 patients who underwent thora-
cotomy, 15 patients died postoperatively, and 138 patients
had cardiorespiratory complications. Causes of death are
shown in Table 3. Complications were grouped by either a
complicated course (cardiorespiratory complications) or poor
outcome (respiratory failure or surgical death) in Tables 4–7.
Patients with a percentage predicted exercise VO2 of 65%
were significantly more likely to have a complicated course
(p  0.0001) and a poor outcome (p  0.0356).
The original study plan was to accrue 90 high-risk
patients. However, after the 51 patients in the high-risk group
and 68 patients in the very high-risk group had undergone
thoracotomy with an acceptable mortality rate, it was thought
that the primary study question about the safety of a thora-
cotomy within the high-risk group had been answered.
Among the 51 high-risk patients, one patient died postoper-
atively within 30 days, whereas among the 68 patients in the









Male 162 64% 43 68% 40 47% 245
Female 92 36% 20 32% 46 53% 158
Race
White 227 89% 61 97% 79 92% 367
Hispanic 4 2% 0 0% 0 0% 4
African American 19 7% 2 3% 4 5% 25
Asian 2 1% 0 0% 1 1% 3
American Indian or
Alaska Native
0 0% 0 0% 2 2% 2
Other 2 1% 0 0% 0 0% 2
Age, yr
40 1 0% 1 2% 1 1% 3
40–49 18 7% 2 3% 1 1% 21
50–59 54 21% 13 21% 15 17% 82
60–69 95 37% 28 44% 28 33% 151
70–79 72 28% 17 27% 37 43% 126
80 14 6% 2 3% 4 5% 20
FIGURE 1. Distribution of Cancer and Leukemia Group B
(CALGB) patients in the CALGB 9238 algorithm. FEV1-ppo,
predicted postoperative forced expiratory volume in 1 sec-
ond; VO2, oxygen consumption.
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very high-risk group, there was also only one postoperative
death within 30 days but a total of three in-hospital deaths. Of
149 patients in the high-risk or physician discretion group,
only 3% died, which represented a value much lower than the
benchmark of 10% postoperative mortality as articulated in
the study’s design.
CALGB 9238 patients were retrospectively evaluated
by the FO algorithm described by Wyser (Figure 2). Of the
312 patients who had sufficient baseline data so that the FO
algorithm could be applied, 182 were determined to be
candidates for resection up to a pneumonectomy, 22 were
determined to be candidates for resection up to the calculated
TABLE 2. Extent of Resection for Patient Groups Categorized by the CALGB 9238 Algorithm
Extent of Resection Low-risk Thoracotomy High-risk Thoracotomy Physician Discretion Total
Pneumonectomy 44 (17%) 6 (10%) 3 (3%) 53 (13%)
Lobe 149 (59%) 34 (54%) 30 (35%) 213 (53%)
Lobe 30 (12%) 10 (16%) 33 (38%) 73 (18%)
No surgery 27 (11%) 12 (19%) 18 (21%) 57 (14%)
Thoracotomy without resection 4 (2%) 1 (1%) 2 (2%) 7 (2%)
Total 254 63 86 403
CALGB, Cancer and Leukemia Group B.
TABLE 3. Surgical Mortality and Causes of Death
Age, Yr Sex FEV1% DLCO% Vo2/kg Vo2% Resection Cause of Death
68 Male 99 35 15 62 Pneumonectomy Myocardial infarction
63 Male 100 100 22 81 Pneumonectomy Pneumonia, respiratory failure
69 Male 62 73 12 49 Pneumonectomy Pneumonia, respiratory failure
61 Male 55 64 24 84 Pneumonectomy Pulmonary embolism
48 Female 83 90 14 92 Pneumonectomy Pneumonia, respiratory failure
72 Male 57 82 18 83 Lobectomy Pneumonia, respiratory failure
45 Female 84 64 18 — Pneumonectomy Respiratory failure
82 Male 75 57 11 53 Lobectomy Pneumonia, respiratory failure
81 Male 85 72 14 77 Pneumonectomy Pulmonary artery laceration
73 Male 79 91 14 43 Pneumonectomy Empyema and bronchopleural fistula
71 Female 68 119 9 58 Lobectomy Pneumonia, respiratory failure
68 Female 67 69 13 74 Lobectomy Pneumonia, respiratory failure
59 Male 25 114 14 54 Lobectomy Empyema and bronchopleural fistula
74 Female 62 121 11 50 Lobectomy Myocardial infarction
71 Male 95 64 19 56 Pneumonectomy Respiratory failure
FEV1, forced expiratory volume in 1 second; DLCO, single breath diffusion capacity; VO2, oxygen consumption.
TABLE 4. Outcomes for Patient Groups Categorized by the CALGB 9238 Algorithm
Patients with Surgery
Variable Low Risk High Risk Very High Riskb No Surgery
Na 227 51 68 57
FEV1 (mean  SE) 83.9  1.3 50.9  1.7 44.8  1.6 64.0  5.3
DLCO (mean  SE) 78.0  1.6 66.6  3.7 60.7  3.2 69.4  3.7
Vo2% (mean  SE) 75.9  1.4 73.4  2.4 56.9  2.0 60.2  2.4
Vo2/kg (mean  SE) 17.0 (0.29) 17.9 (0.40) 12.0 (0.24) 14.4 (0.57)
FVC (mean  SE) 91.9  1.2 71.2  2.3 63.7  1.8 78.6  3.3
% Sublobar resection 13% 20% 49%
5-Yr survival (95% CI)c 0.41 (0.34–0.49) 0.34 (0.21–0.54) 0.27 (0.17–0.42) 0.07 (0.03–0.20)
CALGB, Cancer and Leukemia Group B; DLCO, single breath diffusion capacity; Pred, predicted; FEV1, forced expiratory
volume in 1 second; FVC, forced vital capacity; VO2, oxygen consumption.
a The sample size involved with the calculation of each statistic sometimes varied from what is noted here due to missing data.
b Thoracotomy optional.
c Median follow-up of 83 months.
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extent required, and 108 were determined to be unacceptable
surgical candidates. Among the patients who underwent sur-
gery on CALGB 9238, there were 193 and 58 patients for
whom application of the FO algorithm would have permitted
surgery or denied surgery, respectively. There was no statis-
tically significant difference in the complication rates (surgi-
cal death, cardiorespiratory complications) between the 193
CALGB patients defined as operable by the FO algorithm,
and the 58 patients that would have been considered inoper-
able. Patients who underwent surgery had a median survival
time of 30.9 months, whereas patients who did not undergo
surgery had a median survival time of 15.6 months (p 
0.00003) (Figure 3).
DISCUSSION
We found that exercise VO2 was a significant predictor
of operative mortality and morbidity, consistent with other
investigators.4–6,9,14,17 With regard to the primary hypothesis
of the study, we were able to confirm that patients with a low
FEV1 could tolerate lung resection with acceptable mortality
and morbidity, provided that peak VO2 exceeded the thresh-
old of 15 ml/min/kg or 60% of predicted, consistent with
previous investigators.7 In addition, we found that thoracic
surgeons were able to select patients who were outside these









DLCO % Pred 73.84  1.47 65.75  4.33 8.09 (0.76 to 16.94) 0.0731
FEV1 % Pred 71.87  1.45 69.00  3.39 2.87 (5.87 to 11.60) 0.5191
FVC % Pred 83.62  1.22 81.92  3.11 1.70 (5.71 to 9.11) 0.6518
VO2 % Pred 72.58  1.20 64.80  3.06 7.78 (0.53–7.78) 0.0356
Peak VO2/kg 16.28  0.25 14.71  0.70 1.56 (0.06–3.08) 0.041
Values given are mean  SE. For abbreviations, see footnote to Table 6.
TABLE 5. Frequency of Complications for Patients with a
Complicated Course or Poor Outcome
Complicated Course Poor Outcome
Subjects, no. 138 35
Red blood cell transfusion 38 19
Postoperative fever 57 22
Duration of fever 9 2
Wound infection 7 4
Empyema, absent fistula 6 1
Empyema, fistula present 5 2
Prolonged air leak 21 8
Atelectasis 6 5
Pneumonia 45 18
Respiratory failure 33 33
Dysrhythmia 82 14
Myocardial infarction 2 2
Deep vein thrombosis 2 0
Pulmonary embolism 4 1
Postoperative death 14 15
Complicated course, any cardiorespiratory complication; poor outcome, surgical
death or respiratory failure.
TABLE 6. Baseline Pulmonary Function Data for Patients




DLCO% Pred 76.71  1.77 67.41  2.19 9.30 (3.78–14.83) 0.0010
FEV1% Pred 75.44  1.80 65.78  1.90 9.66 (4.35–14.97) 0.0004
FVC% Pred 85.79  1.44 79.94  1.82 5.85 (1.31–10.39) 0.0118
Vo2% Pred 75.34  1.43 66.55  1.75 8.80 (4.36–13.23) 0.0001
Peak Vo2/kg 16.71  0.30 15.24  0.36 1.47 (0.55–2.4) 0.0019
Values given are mean  SE. CI, confidence interval; DLCO, single breath
diffusion capacity; Pred, predicted; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; VO2, oxygen consumption.
FIGURE 2. Distribution of Cancer and Leukemia Group B
Patients applying the functional operability (FO) algorithm.
*VO2 corrected for body mass in kilograms (ml/min/kg).
FEV1, forced expiratory volume in 1 second; ppo, predicted
postoperative; DLCO, single breath diffusion capacity;
VO2, oxygen consumption; VO2 max, maximal oxygen
consumption.
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accepted parameters, with acceptable mortality and morbid-
ity. This finding is of key importance because patients who
did not go to surgery for suspected lung cancer had a median
survival of 15.8 months compared with 36.0 months (p 
0.00003) for those who went to surgical resection. Although
patients were not randomized and the possibility of bias must
be considered, our data are consistent with the concept that
survival with nonsurgical treatment of lung cancer is poor23
and surgery results in a significant improvement in survival
compared with a nonsurgical approach.24
This study was designed to attract high-risk patients,
some of whom might ordinarily be denied surgery by con-
ventional criteria, and we were prepared to accept an opera-
tive mortality rate of as high as 10% in these high-risk
subsets. Our overall operative mortality rate of 4% was
somewhat higher than what has been reported most recently
by the American College of Surgeons Oncology Group25 in
part due to the poorer pulmonary function that was seen in
our patient cohort. The definition of surgical mortality in this
study was extended beyond the 30-day period because many
patients who fail to thrive after lung resection will eventually
die of chronic respiratory disease in the hospital, and four of
the 15 surgical deaths were included for this reason even
though they occurred after the 30-day period. Consistent with
other investigators, we found that mortality was closely
linked to the extent of resection.26–29 Although lobar, seg-
mental, or wedge resections may be done primarily by video-
assisted thoracic surgery in low FEV1 patients30 with accept-
able risk, more extensive resections that include open
thoracotomy and resection up to pneumonectomy would be
expected to entail a higher mortality and morbidity.
It has been argued that the FO algorithm will eliminate
unnecessary radionuclear scanning in some patients and is
more cost-effective than accepted algorithms,15 with further
cost savings because of reduced complication rates. We agree
with this assertion and have been able to show that this
approach is feasible in the setting of a multi-institutional trial.
It is of note that postoperative respiratory failure is one of the
most costly of all postoperative complications31 and peak VO2
measurement was uniquely useful in identifying subjects at
risk of this complication. Evidence suggests that operative
risk may also be assessed with stair climbing,32–34 and this
approach would also be economical, but outcome data com-
paring direct measurement of peak VO2 with a stair climbing–
based estimation of exercise capacity are not available. Given
the variability in stair height, stairs per flight, and climbing
rate, as well as the unmonitored nature of this informal stress
test, it is our view that it is better to quantify the degree of
exercise impairment with direct measurement of peak VO2
when possible.
In summary, our results have shown that patients who
had a peak exercise VO265% of predicted were more likely
to suffer complications (p  0.0001) and were more likely to
have a poor outcome (respiratory failure or death) (p 
0.0356). Our results also indicate that patients with an FEV1
of70% of predicted and a DLCO of70% of predicted are
medically operable and do not require further testing, and
patients with an FEV1 or DLCO 70% of predicted who
have a peak VO2 15 ml/min/kg or 65% of predicted are
medically operable and do not require further testing. None-
theless, even high-risk patients may be considered for
life-saving lung resection with acceptable morbidity and
mortality; we found that experienced thoracic surgeons
were successful at predicting which patients would do
reasonably well. Patients may be willing to accept a higher
rate of complications to have the chance of cure of their
lung cancer because those who do not have surgery have a
dismal outcome.
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